BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Seto WK. Hepatitis B virus reactivation during immunosuppressive therapy: Appropriate risk stratification. World J Hepatol 2015; 7(6): 825-830 [PMID: 25937860 DOI: 10.4254/wjh.v7.i6.825]
URL: https://www.wjgnet.com/1948-5182/full/v7/i6/825.htm
Number Citing Articles
1
C. Cerva, G. Maffongelli, V. Svicher, R. Salpini, L. Colagrossi, A. Battisti, B. Mariotti, R. Cerretti, L. Cudillo, L. Sarmati. Hepatitis B reactivation characterized by HBsAg negativity and anti-HbsAg antibodies persistence in haematopoietic stem cell transplanted patient after lamivudine withdrawalBMC Infectious Diseases 2017; 17(1) doi: 10.1186/s12879-017-2672-6
2
Hae Lim Lee, Jeong Won Jang, Ji Won Han, Sung Won Lee, Si Hyun Bae, Jong Young Choi, Nam Ik Han, Seung Kew Yoon, Hee-Je Kim, Seok Lee, Seok-Goo Cho, Chang-Ki Min, Dong-Wook Kim, Jong Wook Lee. Early Hepatitis B Surface Antigen Seroclearance Following Antiviral Treatment in Patients with Reactivation of Resolved Hepatitis BDigestive Diseases and Sciences 2019; 64(10): 2992 doi: 10.1007/s10620-019-05614-6
3
Lorraine Jennings, Oonagh Molloy, Catherine Quinlan, Genevieve Kelly, Marina O'Kane. Treatment of pyoderma gangrenosum, acne, suppurative hidradenitis (PASH) with weight‐based anakinra dosing in a Hepatitis B carrierInternational Journal of Dermatology 2017; 56(6) doi: 10.1111/ijd.13528
4
Olga Timofeeva, James Brown. Immunological considerations—HLA matching and management of high immunological risk recipientsIndian Journal of Thoracic and Cardiovascular Surgery 2022; 38(S2): 248 doi: 10.1007/s12055-021-01201-5
5
Forough Golsaz-Shirazi, Fazel Shokri. Hepatitis B Immunopathogenesis and ImmunotherapyImmunotherapy 2016; 8(4): 461 doi: 10.2217/imt.16.3
6
Alessandro Loglio, Mauro Viganò, Glenda Grossi, Sara Labanca, Maria Goldaniga, Alessandra Pompa, Lucia Farina, Mariagrazia Rumi, Paolo Corradini, Floriana Facchetti, Giovanna Lunghi, Luca Baldini, Pietro Lampertico. Lamivudine prophylaxis prevents hepatitis B virus reactivation in anti-HBc positive patients under rituximab for non-Hodgkin lymphomaDigestive and Liver Disease 2019; 51(3): 419 doi: 10.1016/j.dld.2018.08.024
7
Yi-Chia Su, Pei-Chin Lin, Hsien-Chung Yu, Chih-Chien Wu. Antiviral prophylaxis during chemotherapy or immunosuppressive drug therapy to prevent HBV reactivation in patients with resolved HBV infection: a systematic review and meta-analysisEuropean Journal of Clinical Pharmacology 2018; 74(9): 1111 doi: 10.1007/s00228-018-2487-4
8
Tomasz I. Michalak. Diverse Virus and Host-Dependent Mechanisms Influence the Systemic and Intrahepatic Immune Responses in the Woodchuck Model of Hepatitis BFrontiers in Immunology 2020; 11 doi: 10.3389/fimmu.2020.00853
9
Martin Feuchtenberger, Arne Schäfer, Axel Philipp Nigg, Michael Rupert Kraus. Hepatitis B Serology in Patients with Rheumatic DiseasesThe Open Rheumatology Journal 2016; 10(1): 39 doi: 10.2174/1874312901610010039
10
Pranatharthi H. Chandrasekar, Miriam T. Levine. Occult Hepatitis B Virus Reactivation in a Seronegative Stem Cell Transplant RecipientInfectious Diseases in Clinical Practice 2017; 25(2): 97 doi: 10.1097/IPC.0000000000000472
11
R. Pereira, I. Raposo, F. Nery, T. Torres. Risk of hepatitis B virus reactivation in patients treated with anti-TNFα agents for immune-mediated inflammatory diseasesActas Dermo-Sifiliográficas (English Edition) 2018; 109(3): 285 doi: 10.1016/j.adengl.2017.07.018
12
Anca Raducan, Stefana Bucur, Constantin Caruntu, Traian Constantin, Iuliana Nita, Nicuta Manolache, Maria-Magdalena Constantin. Therapeutic management with biological anti-TNF-α agent in severe psoriasis associated with chronic hepatitis B: A case reportExperimental and Therapeutic Medicine 2019;  doi: 10.3892/etm.2019.7567
13
Shih-Yu Yang, Tsung-Hui Hu, Yeh-Pin Chou, Yuan-Hung Kuo, Ming-Chao Tsai, Kuo-Chin Chang, Yi-Hao Yen, Po-Lin Tseng. Long-term comparisons of the durability of 6 months versus 12 months antiviral therapy for hepatitis B after chemotherapy cessationJournal of Infection and Public Health 2023; 16(11): 1852 doi: 10.1016/j.jiph.2023.08.006
14
Ka-Shing Cheung, Wai-Kay Seto, Ching-Lung Lai, Man-Fung Yuen. Prevention and management of hepatitis B virus reactivation in cancer patientsHepatology International 2016; 10(3): 407 doi: 10.1007/s12072-015-9692-3
15
Hae Lim Lee, Si Hyun Bae, Bohyun Jang, Seawon Hwang, Hyun Yang, Hee Chul Nam, Pil Soo Sung, Sung Won Lee, Jeong Won Jang, Jong Young Choi, Nam Ik Han, Byung Joo Song, Jong Wook Lee, Seung Kew Yoon. Reactivation of Hepatitis C Virus and Its Clinical Outcomes in Patients Treated with Systemic Chemotherapy or Immunosuppressive TherapyGut and Liver 2017; 11(6): 870 doi: 10.5009/gnl16434
16
R. Pereira, I. Raposo, F. Nery, T. Torres. Risk of hepatitis B virus reactivation in patients treated with anti-TNFα agents for immune-mediated inflammatory diseasesActas Dermo-Sifiliográficas 2018; 109(3): 285 doi: 10.1016/j.ad.2017.07.011
17
Xueyuan Nian, Zhihui Xu, Yan Liu, Jianhong Chen, Xiaodong Li, Dongping Xu. Association between hepatitis B virus basal core promoter/precore region mutations and the risk of hepatitis B-related acute-on-chronic liver failure in the Chinese population: an updated meta-analysisHepatology International 2016; 10(4): 606 doi: 10.1007/s12072-016-9716-7
18
Rex Wan-Hin Hui, Lung Yi Mak, Wai-Kay Seto, Man-Fung Yuen. Assessing the developing pharmacotherapeutic landscape in hepatitis B treatment: a spotlight on drugs in phase II clinical trialsExpert Opinion on Emerging Drugs 2022; 27(2): 127 doi: 10.1080/14728214.2022.2074977
19
Maria Guarino, Marco Picardi, Anna Vitiello, Novella Pugliese, Matilde Rea, Valentina Cossiga, Fabrizio Pane, Nicola Caporaso, Filomena Morisco. Viral Outcome in Patients with Occult HBV Infection or HCV-Ab Positivity Treated for LymphomaAnnals of Hepatology 2017; 16(2): 198 doi: 10.5604/16652681.1231579